Internal Medicine, Rheumatology · Pensacola, FL
NPI
1720039175
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
5190 Bayou Blvd Ste 2
Pensacola, FL, 32503
Phone (850) 746-0560
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
106,467 services
Medicare patients, 2024
429
Average age 71
Drug cost, 2024
$6.3M
7,886 prescriptions
Company payments, 2025
$3,978
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher D Adams was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 29,200 times for 11 patients. In total Christopher D Adams billed 106,467 services in 63 codes, and Medicare paid $1.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 29,200 | 11 | $3.58 | $105K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,600 | 17 | $9.10 | $96K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,450 | 18 | $33.19 | $280K |
| J0897 Injection, denosumab, 1 mg | Office | 3,600 | 37 | $20.22 | $73K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 554 | 96 | $0.71 | $393 |
| 99214 Office E&M - Established | Office | 477 | 346 | $81.99 | $39K |
| 96413 Chemotherapy Administration | Office | 336 | 57 | $90.73 | $30K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 311 | 266 | $12.41 | $3,858 |
| 96401 Chemotherapy Administration | Office | 222 | 50 | $50.97 | $11K |
| 99215 Office E&M - Established | Office | 94 | 74 | $124.14 | $12K |
| 20610 Joint Injection | Office | 60 | 36 | $42.12 | $2,527 |
| 99213 Office E&M - Established | Office | 52 | 47 | $54.70 | $2,844 |
| 20552 Musculoskeletal | Office | 38 | 29 | $27.13 | $1,031 |
| 96372 Injection Administration | Office | 28 | 25 | $9.72 | $272 |
| 20600 Joint Injection | Office | 27 | 15 | $31.40 | $848 |
By year: 2022 $1.6M for 77,957 services; 2023 $1.6M for 99,001 services; 2024 $1.4M for 106,467 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher D Adams prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 595 prescriptions and refills. In total Christopher D Adams wrote 7,886 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 595 | 1,428 | 304 | $54K |
| Gabapentin Generic | 352 | 813 | 171 | $6,478 |
| Methotrexate Methotrexate Sodium | 342 | 723 | 173 | $15K |
| Tramadol Hcl Generic | 306 | 332 | 120 | $2,298 |
| Prednisone Generic | 286 | 465 | 156 | $2,547 |
| Duloxetine Hcl Generic | 285 | 712 | 136 | $7,514 |
| Diclofenac Sodium Generic | 171 | 257 | 95 | $5,858 |
| Azathioprine Generic | 158 | 294 | 65 | $8,105 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 152 | 158 | 36 | $3,500 |
| Cyclobenzaprine Hcl Generic | 150 | 301 | 83 | $1,049 |
| Pregabalin Generic | 138 | 278 | 56 | $5,447 |
| Mycophenolate Mofetil Generic | 134 | 258 | 70 | $19K |
| Meloxicam Generic | 133 | 355 | 80 | $698 |
| Leflunomide Generic | 129 | 297 | 68 | $16K |
| Calcitonin-Salmon Calcitonin,salmon,synthetic | 127 | 158 | 57 | $8,815 |
Brand drugs: 1,197 claims; generic drugs: 6,675 claims; opioid claims: 618.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher D Adams $3,978 ($3,978 in general payments such as food, travel and fees) from 23 companies. The largest payer was Abbvie Inc. with $688.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 31 | $688 |
| Pfizer Inc. PFE | 15 | $390 |
| UCB, Inc. UCB.BR | 19 | $376 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $330 |
| Amgen Inc. AMGN | 21 | $328 |
| Mallinckrodt Hospital Products Inc. | 9 | $284 |
| GlaxoSmithKline, LLC. GSK | 10 | $252 |
| Radius Health, Inc. | 8 | $243 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $222 |
| Janssen Biotech, Inc. JNJ | 9 | $165 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.